Medical Innovation Slows

US exclusion from WHO’s ACT Accelerator will hinder access to new diagnostics and treatments developed through global collaboration. Technology companies might hesitate to join collaborations without WHO’s unified approach to standards and implementation. Global health startups face uncertain funding environments as investment patterns shift. ACT partners spent 2025 reassessing their roles in this changing landscape. Breakthrough treatments might reach fewer patients. Development costs rise without shared research platforms.